Drug Trial Radar · NCT05807399
PanACEA - STEP2C -01
Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Apr 14, 2023
Primary completion
Oct 31, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Michael HoelscherAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Radboud University Medical Center; University of California, San Francisco; University College, London; GlaxoSmithKline; LigaChem Biosciences, Inc.
- First posted
- Apr 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2B/C, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis. In stage 1, participants will be randomly allocated to the control or one of the 2 rifampicin-containing experimental regimens in the ratio 1:1:1. In stage 2, the experimental arm 4 containing BTZ-043 will be added. The allocation ratio will be changed to co-enrol the remaining participants in arms 1- 3 simultaneously with arm 4 in a ratio of 1:1:1:2. When arms 1-2 are fully enrolled and arm 4 is not, further participants will be randomized 1:1 to control and experimental arm 4. Not all countries will participate in stage 2. In stage 3, participants will be allocated in parallel to control arm treatment (now designated arm 7) or the experimental arms 5 and 6, favouring arm 5, 2:1:1 over arms 6 and control. This stage will start after completion of recruitment in the stages 1 and 2. Enrolment of participants into arm 5 will proceed following review of data from the ENABLE/UNITE-03 (NCT06748937), non-clinical safety data and after endorsement by the DSMB. Thus, arm 5 recruitment might start after arms 6 and 7, which may require an increase in the control arm sample size to ensure controls are recruited concomitantly.
Conditions
- Pulmonary Tuberculosis
- Other Specified Pulmonary Tuberculosis
Interventions
BTZ-043Drug
BTZ-043 1000mg once daily in arms 4 and 6.
RifampicinDrug
Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3, 5 and 7.
IsoniazidDrug
Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3 and 7.
PyrazinamideDrug
Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3, 5 and 7.
MoxifloxacinDrug
Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2.
Alpibectir (GSK3729098)Drug
Alpibectir 45 mg OD plus Ethionamide 500 mg OD combined with rifampicin pyrazinamide and ethambutol at standard weight-banded doses in arm 5.
Ganfeborole (GSK3036656)Drug
Ganfeborole 20 mg OD in arm 6
Delpazolid (LCB01-0371)Drug
Delpazolid 1200mg OD in arm 6
Pretomanid (Pa)Drug
Pretomanid 20mg OD in arm 6.
Ethambutol (E)Drug
Ethambutol 20mg/Kg OD in arm 3, 5 and 7
EthionamideDrug
Ethionamide 500mg OD in arm 5.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to stable culture conversion to negative in liquid mediaTime frame: Day 01- Week 26
- Change in Mycobacterial load (Stage 3)Time frame: Baseline until week 12 of treatment.
Locations
10 sites in 6 countries. Site status is shown where the registry gives one.
Centre de Recherches Médicales de Lambaréné (CERMEL)
Lambaréné, Gabon · Completed
Kamuzu College of Health Sciences (formerly College of Medicine)
Blantyre, Malawi · Recruiting
Instituto Nacional de Saúde (INS)
Maputo, Mozambique · Recruiting
TASK Applied Sciences Clinical Research Centre
Cape Town, South Africa · Recruiting
University of Cape Town Lung Institute
Cape Town, South Africa · Not yet recruiting
Isango Lethemba TB Research Unit. Clinical HIV Research Unit (CHRU), Wits Health Consortium.
Port Elizabeth, Eastern Cape, South Africa · Not yet recruiting
Ifakara Health Institute (IHI)
Bagamoyo, Tanzania · Recruiting
Kilimanjaro Clinical Research Institute (KCRI)
Moshi, Tanzania · Recruiting
National Institute for Medical Research (NIMR-MMRC)
Mbeya, Mbeya, Tanzania · Recruiting
Makerere University Lung Institute Limited
Kampala, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.